Mentioned in ?
References in periodicals archive ?
Cruickshank, "The clinical importance of cardioselectivity and lipophilicity in beta blockers," American Heart Journal, vol.
In conclusion, cardioselectivity is paramount, and therefore metoprolol, bisoprolol and in particular nebivolol should be the first choice treatment.
The first factor is cardioselectivity. These agents, which include bisoprolol, metoprolol, atenolol, and acebutolol, are thought to selectively target the beta-receptors in the cardiovascular system and, thus, are safer to use in patients with asthma or chronic obstructive pulmonary disease due to the fact that exacerbations occur when the beta-1 receptors found in the lungs are blocked.